US-based polyclonal antibody developer SAB Biotherapeutics today completed a $14m series B round featuring pharmaceutical firm Merck & Co.
The round was filled out by private equity firm South Dakota Equity Partners and multiple unnamed existing and private investors.
SAB Biotherapeutics is working on immunotherapies using a polyclonal antibody platform to address a range of diseases, including a phase 2-stage candidate, SAB-301, for Middle East respiratory syndrome (Mers) coronavirus – a form of contagious respiratory virus that can be fatal.
The company has also pivoted to prepare a potential Covid-19 drug for clinical trials later in July 2020 having expedited the program in response to the pandemic.
SAB Biotherapeutics has now secured $50m of equity funding, including $22m of series A2 funding in a round closed in late 2018 with $1m from South Dakota Equity Partners and further contributions from undisclosed investors.